Suzhou Highfine Biotech Co., Ltd. (SHE:301393)
China · Delayed Price · Currency is CNY 64.16
+0.66 (1.04%)
At close: May 25, 2026
Suzhou Highfine Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 638.41 | 601.69 | 451.87 | 388.79 | 447.46 | 369.43 |
Other Revenue | 0.57 | 0.57 | - | - | - | 0.01 |
| 638.98 | 602.26 | 451.87 | 388.79 | 447.46 | 369.44 | |
Revenue Growth (YoY) | 28.86% | 33.28% | 16.22% | -13.11% | 21.12% | 30.85% |
Cost of Revenue | 427.3 | 399.11 | 272.51 | 243.44 | 254.68 | 197.97 |
Gross Profit | 211.69 | 203.15 | 179.36 | 145.36 | 192.78 | 171.47 |
Selling, General & Admin | 58.63 | 53.25 | 43.13 | 35.97 | 25.25 | 24.48 |
Research & Development | 41.75 | 40.93 | 35.99 | 28.47 | 22.26 | 14.8 |
Other Operating Expenses | 6.96 | 6.51 | 4.18 | 1.71 | 3.39 | 3.14 |
Operating Expenses | 107.01 | 100.4 | 85.07 | 66.15 | 50.9 | 44.03 |
Operating Income | 104.67 | 102.75 | 94.29 | 79.21 | 141.88 | 127.44 |
Interest Expense | -0.82 | -0.7 | -0.09 | -0.05 | -0.24 | -0.09 |
Interest & Investment Income | 27.84 | 33.72 | 40.68 | 29.01 | 1.07 | 1.96 |
Currency Exchange Gain (Loss) | -7.33 | -7.33 | 3.33 | -0.01 | 3.71 | -2.33 |
Other Non Operating Income (Expenses) | -1.02 | 1.91 | -0.89 | -0.18 | -0.16 | -0.13 |
EBT Excluding Unusual Items | 123.34 | 130.35 | 137.32 | 107.98 | 146.26 | 126.86 |
Gain (Loss) on Sale of Investments | 10.45 | 7.24 | 5.64 | 0.22 | - | 0 |
Gain (Loss) on Sale of Assets | -0.75 | -0.91 | -0.03 | -0 | -0.12 | -0.03 |
Asset Writedown | -14.34 | -14.1 | -0.36 | -0.08 | -0.28 | -0.08 |
Other Unusual Items | 7.81 | 6.67 | 12.07 | 4.37 | 3.11 | 2.3 |
Pretax Income | 126.53 | 129.27 | 154.64 | 112.49 | 148.96 | 129.05 |
Income Tax Expense | 17.77 | 18.43 | 20.58 | 13.51 | 19.59 | 17.65 |
Earnings From Continuing Operations | 108.76 | 110.84 | 134.05 | 98.97 | 129.37 | 111.4 |
Minority Interest in Earnings | 4.54 | 3.81 | - | - | - | - |
Net Income | 113.3 | 114.65 | 134.05 | 98.97 | 129.37 | 111.4 |
Net Income to Common | 113.3 | 114.65 | 134.05 | 98.97 | 129.37 | 111.4 |
Net Income Growth | -18.50% | -14.47% | 35.44% | -23.50% | 16.13% | 175.73% |
Shares Outstanding (Basic) | 108 | 107 | 107 | 92 | 81 | 81 |
Shares Outstanding (Diluted) | 108 | 107 | 108 | 92 | 81 | 81 |
Shares Change (YoY) | -0.86% | -0.92% | 16.97% | 14.40% | 0.16% | -0.10% |
EPS (Basic) | 1.05 | 1.07 | 1.25 | 1.07 | 1.60 | 1.38 |
EPS (Diluted) | 1.05 | 1.07 | 1.24 | 1.07 | 1.60 | 1.38 |
EPS Growth | -17.79% | -13.68% | 15.79% | -33.13% | 15.94% | 176.00% |
Free Cash Flow | -175 | -133.16 | 18.62 | -32.64 | 57.27 | 22.42 |
Free Cash Flow Per Share | -1.62 | -1.24 | 0.17 | -0.35 | 0.71 | 0.28 |
Dividend Per Share | 0.405 | 0.405 | 0.390 | 0.250 | 0.250 | 2.500 |
Dividend Growth | 3.85% | 3.85% | 56.00% | - | -90.00% | - |
Gross Margin | 33.13% | 33.73% | 39.69% | 37.39% | 43.08% | 46.41% |
Operating Margin | 16.38% | 17.06% | 20.87% | 20.37% | 31.71% | 34.50% |
Profit Margin | 17.73% | 19.04% | 29.67% | 25.46% | 28.91% | 30.15% |
Free Cash Flow Margin | -27.39% | -22.11% | 4.12% | -8.40% | 12.80% | 6.07% |
EBITDA | 145.18 | 138.81 | 112.56 | 92.14 | 152.28 | 133.62 |
EBITDA Margin | 22.72% | 23.05% | 24.91% | 23.70% | 34.03% | 36.17% |
D&A For EBITDA | 40.5 | 36.06 | 18.27 | 12.94 | 10.41 | 6.18 |
EBIT | 104.67 | 102.75 | 94.29 | 79.21 | 141.88 | 127.44 |
EBIT Margin | 16.38% | 17.06% | 20.87% | 20.37% | 31.71% | 34.50% |
Effective Tax Rate | 14.04% | 14.25% | 13.31% | 12.01% | 13.15% | 13.68% |
Revenue as Reported | 638.98 | 602.26 | 451.87 | 388.79 | 447.46 | 369.44 |
Advertising Expenses | - | 2.27 | 2.36 | 2.03 | 0.47 | 0.64 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.